Ny Teknik & Affärsvärlden list SenzaGen AB as one of the 33 most promising young innovative companies in Sweden.

SenzaGen rated one of Sweden´s most promising companies On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden. After several interviews by the organisers, a challenging questioning by an initiated jury and a smashing elevator pitch, Senzagen acquired a position on the renowned 33-list. The 33-list is based on propositions of […]

SenzaGen rated one of Sweden´s most promising companies
On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden.
After several interviews by the organisers, a challenging questioning by an initiated jury and a smashing elevator pitch, Senzagen acquired a position on the renowned 33-list.

The 33-list is based on propositions of companies from all over Sweden and the winners are chosen collectively by the editorial staff at the two journals Ny Teknik and Affärsvärlden. The jury is looking for companies with a unique product or service based on a clear innovation with great international potential – an innovation with the ability to change the rules in the business. To qualify for a position on the list, the company must be based in Sweden and be less than 7 years. Read more on http://www.33-listan.se

Link to the article in Ny Teknik 2015, March 2: http://www.nyteknik.se/33listan/article3889772.ece

senzagen maria agemark

Maria Agemark new quality manager at SenzaGen

SenzaGen is in an expansive phase and is building up its team with new personnel. Maria Agemark has been recruited as quality manager and was previously working at the Department Immunotechnology at LTH . Maria has a PhD in biochemistry, where she conducted research on the Aquaporins in humans and plants. – It is going […]

SenzaGen is in an expansive phase and is building up its team with new personnel. Maria Agemark has been recruited as quality manager and was previously working at the Department Immunotechnology at LTH . Maria has a PhD in biochemistry, where she conducted research on the Aquaporins in humans and plants.

– It is going to be exciting and challenging to work in a new company that is in an exciting early phase. I know the research behind the products well and look forward to be part of the new team that SenzaGen is setting up, says Maria Agemark .

Maria starts on SenzaGen in March 2015 and will focus on building up the new lab and quality systems.

– Maria has an expertise that we need to bring the company to the next level. I very much look forward to working together with Maria, says Anki Malmborg Hager, CEO of SenzaGen.

Systematic evaluation of non-animal test methods for skin sensitisation safety assessment.

Toxicology in Vitro   Volume 29, Issue 1, February 2015, Pages 259–270 Kerstin Reisinger, Sebastian Hoffmann, Nathalie Alépée, Takao Ashikaga, Joao Barroso, Cliff Elcombe, Nicola Gellatly, Valentina Galbiati, Susan Gibbs, Hervé Groux, Jalila Hibatallah, Donald Keller, Petra Kern, Martina Klaric, Susanne Kolle, Jochen Kuehnl, Nathalie Lambrechts, Malin Lindstedt, Marion Millet, Silvia Martinozzi-Teissier, Andreas Natsch, Dirk Petersohn, […]
Toxicology in Vitro   Volume 29, Issue 1, February 2015, Pages 259–270

Kerstin Reisinger, Sebastian Hoffmann, Nathalie Alépée, Takao Ashikaga, Joao Barroso, Cliff Elcombe, Nicola Gellatly, Valentina Galbiati, Susan Gibbs, Hervé Groux, Jalila Hibatallah, Donald Keller, Petra Kern, Martina Klaric, Susanne Kolle, Jochen Kuehnl, Nathalie Lambrechts, Malin Lindstedt, Marion Millet, Silvia Martinozzi-Teissier, Andreas Natsch, Dirk Petersohn, Ian Pike, Hitoshi Sakaguchi, Andreas Schepky, Magalie Tailhardat, Marie Templier, Erwin van Vliet, Gavin Maxwell

 

Abstract

The need for non-animal data to assess skin sensitisation properties of substances, especially cosmetics ingredients, has spawned the development of many in vitro methods. As it is widely believed that no single method can provide a solution, the Cosmetics Europe Skin Tolerance Task Force has defined a three-phase framework for the development of a non-animal testing strategy for skin sensitisation potency prediction. The results of the first phase – systematic evaluation of 16 test methods – are presented here. This evaluation involved generation of data on a common set of ten substances in all methods and systematic collation of information including the level of standardisation, existing test data, potential for throughput, transferability and accessibility in cooperation with the test method developers. A workshop was held with the test method developers to review the outcome of this evaluation and to discuss the results. The evaluation informed the prioritisation of test methods for the next phase of the non-animal testing strategy development framework. Ultimately, the testing strategy – combined with bioavailability and skin metabolism data and exposure consideration – is envisaged to allow establishment of a data integration approach for skin sensitisation safety assessment of cosmetic ingredients.

Keywords

Skin sensitisationTesting strategySafety assessmentNon-animal test methodsAdverse Outcome Pathways

Link to article on line

SenzaGen AB completes successful collaboration with Beiersdorf AG.

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf. SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals. SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, […]

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

Beiersdorf has been working in the development and recognition of alternative methods for more than 20 years and is one of the main players in the cosmetic industry in Europe. An industry that is highly interested in recommendations in this field – especially after the ban in March 2013 on animal testing in the cosmetic industry.

“It has been very valuable for SenzaGen to be able to challenge its skin sensitization test in an industrial setting.” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

In the collaboration, blind testing of two industrial test sets of chemicals were performed using the SenzaGen proprietary GARD assay, resulting in an accuracy of 89%.

Lund university

SenzaGen AB attracts financial support from LU Innovation System AB.

LU Innovation System AB (LUIS) has since 1999 been involved in spinning out 69 companies based on research from Lund University. The portfolio has now increased by the investment in SenzaGen AB. “We have a strong connection to Lund University and the investment by LUIS acknowledges our work and provides us with the ability to […]

LU Innovation System AB (LUIS) has since 1999 been involved in spinning out 69 companies based on research from Lund University. The portfolio has now increased by the investment in SenzaGen AB.

“We have a strong connection to Lund University and the investment by LUIS acknowledges our work and provides us with the ability to take the next important steps in our commercialization strategy,” says Anki Malmborg Hager, CEO of SenzaGen AB.

“We are very pleased of being a partner in Senzagen, which we believe has a great commercial potential. The fact that their technology can replace animal experiments doesn´t make it worse”, says Linus Wiebe, Innovation Director Lund University and CEO LU Innovation System.

The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers and other routes of exposure. Based on the demand from the market the company is now gearing up its commercial operations and prepares for the launch of further products.

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
anki.malmborg.hager@senzagen.com
+46 768 284822

Linus Wiebe, Director of Innovation, LU Innovation Systems AB
linus.wiebe@innovation.lu.se
0733- 451 240

henrik johansson senior scientist

Dr. Henrik Johansson, scientist and COO of SenzaGen AB, was awarded the LUSH Young Researcher Award 2014.

“The project for which Dr. Johansson was awarded, the Lush Prize Young Researcher Award, describes the development and use of the novel test method GARD – Genomic Allergen Rapid Detection, an assay for assessment of chemical sensitizers. …GARD utilises an in vitro model of so-called dendritic cells, a central player in the human immune system. […]

“The project for which Dr. Johansson was awarded, the Lush Prize Young Researcher Award, describes the development and use of the novel test method GARD – Genomic Allergen Rapid Detection, an assay for assessment of chemical sensitizers.

…GARD utilises an in vitro model of so-called dendritic cells, a central player in the human immune system. These cells are stimulated with any substances to be tested, and following an incubation time of 24h, the genetic material of the cells are isolated. By measurements of a certain set of genes in the cells, which could be viewed as on/off-switches of the immune response, the eventual risk of the tested substances ability to induce allergy can be predicted.” [Lush Prize Young Researcher http://www.lushprize.org/2014-prize/2014-prize-winners/]

Read more on Lush Prize Young Researcher Award web site

ann gidner Carl henric

SenzaGen recruits Dr. Carl-Henric Nilsson and Ann Gidner to the Board of Directors

-We are entering into a very exciting commercial phase and are happy to be able to engage board members with international experience from our target markets, says Prof. Carl Borrebaeck, chairman of the board of SenzaGen. Carl-Henric Nilsson holds a PhD and M.Sc. in Industrial management, and is Associate Professor at Lund University, School of […]

-We are entering into a very exciting commercial phase and are happy to be able to engage board members with international experience from our target markets, says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

Carl-Henric Nilsson holds a PhD and M.Sc. in Industrial management, and is Associate Professor at Lund University, School of Economics and Management. He is CEO of Kunskapspartner AB, Chairman of Kunskapspartner Holding AB, Boardmember in FX International AB and Boffins Holding AB. Carl-Henric’s research is focused on Business development and Industrialization with numerous scientific publications. Carl-Henric is working with entrepreneurs on a global basis with a broad contact net, especially in China and the United States.

Ann Gidner holds a Master of Science in Chemical Engineering /Bioprocessing and a Bachelor in Business Administration. She has extensive international experience from the chemical industry with global leading positions in e.g. Cambrex and Lanxess Corporations. Furthermore, she has held managing positions in RFR Solutions AB, Semcon Caran AB, and Monocl AB. She is currently Director of Sales & Business Development Europe at Novozymes Biopharma, Copenhagen.

Other members of the board are chairman Carl Borrebaeck and deputy Malin Lindstedt.

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
anki.malmborg.hager@senzagen.com
+46 768 284822

ceo senzagen anki malmborg hager

SenzaGen recruits Dr. Anki Malmborg Hager as CEO

We are very happy to have been able to recruit Dr. Malmborg, who has extensive experience from commercialization of academic results, financial markets and business developments says Prof.Carl Borrebaeck, chairman of the Board of SenzaGen. Anki Malmborg Hager has more than 20 years´ experience in both pharmaceutical and biotech companies that are spin-offs from the […]

Anki Malmborg Hager, CEO SenzaGen AB

We are very happy to have been able to recruit Dr. Malmborg, who has extensive experience from commercialization of academic results, financial markets and business developments says Prof.Carl Borrebaeck, chairman of the Board of SenzaGen.

Anki Malmborg Hager has more than 20 years´ experience in both pharmaceutical and biotech companies that are spin-offs from the University. She held the position as Investment Director in Lund University Bioscience AB between 2009 and 2011 as well as management positions in eg. Alligator Bioscience AB, XImmune AB (CEO), Cantargia AB (CEO), and Diaprost AB (CEO).

“I am very pleased to have been offered this opportunity” says Anki Malmborg Hager. “The underlying research in SenzaGen is world class and the market window of opportunity is timely and very exciting. I am looking forward to joining the SenzaGen team and to lead the next steps in the commercialization of many years of first-class research”.
For more information please contact:
Carl Borrebaeck, Chairman of the Board, SenzaGen AB
carl.borrebaeck@immun.lth.se
+46 708 218330

Årsredovisning 2014

SenzaGen meddelar idag att årsredovisningen för 2018 finns tillgänglig på svenska. En digital version kan laddas ner på bolagets hemsida www.senzagen.com/investors/rapporter samt kan läsas via länken nedan. 

Genomic allergen rapid detection in-house validation-a proof of concept.

Toxicol Sci. 2014 Jun;139(2):362-70. doi: 10.1093/toxsci/kfu046. Epub 2014 Mar 27. Johansson H., Rydnert F., Kuehnl J., Schepky A., Borrebaeck C.A.K., Lindstedt M. Abstract Chemical sensitization is an adverse immunologic response to chemical substances, inducing hypersensitivity in exposed individuals. Identifying chemical sensitizers is of great importance for chemical, pharmaceutical, and cosmetic industries, in order to prevent […]

Toxicol Sci. 2014 Jun;139(2):362-70. doi: 10.1093/toxsci/kfu046. Epub 2014 Mar 27.

Johansson H., Rydnert F., Kuehnl J., Schepky A., Borrebaeck C.A.K., Lindstedt M.

Abstract

Chemical sensitization is an adverse immunologic response to chemical substances, inducing hypersensitivity in exposed individuals. Identifying chemical sensitizers is of great importance for chemical, pharmaceutical, and cosmetic industries, in order to prevent the use of sensitizers in consumer products. Historically, chemical sensitizers have been assessed mainly by in vivo methods, however, recently enforced European legislations urge and promote the development of animal-free test methods able to predict chemical sensitizers. Recently, we presented a predictive biomarker signature in the myeloid cell line MUTZ-3, for assessment of skinsensitizers. The identified genomic biomarkers were found to be involved in immunologically relevant pathways, induced by recognition of foreign substances and regulating dendritic cell maturation and cytoprotective mechanisms. We have developed the usage of this biomarker signature into a novel in vitro assay for assessment of chemical sensitizers, called Genomic Allergen Rapid Detection (GARD). The assay is based on chemical stimulation of MUTZ-3 cultures, using the compounds to be assayed as stimulatory agents. The readout of the assay is a transcriptional quantification of the genomic predictors, collectively termed the GARD Prediction Signature (GPS), using a complete genome expression array. Compounds are predicted as either sensitizers or nonsensitizers by a Support Vector Machine model. In this report, we provide a proof of concept for the functionality of the GARD assay by describing the classification of 26 blinded and 11 nonblinded chemicals as sensitizers or nonsensitizers. Based on these classifications, the accuracy, sensitivity, and specificity of the assay were estimated to 89, 89, and 88%, respectively.

KEYWORDS:

GARD; allergic contact dermatitis; chemical sensitizers; in vitro assay; predictive assay; skin sensitization

Link to article on line